Valuing the Unvalued: Scientific Promise Is Not Financial Value Why understanding value creation matters for life sciences founders and CEOs. I have worked with many life sciences founders who believe their companies are worth considerably more than investors are willing to pay. The science is compelling. The intellectual property is strong. The clinical opportunity is … Read more
The Scientist’s Financial Education: What You Don’t Know Can Cost You Your Company Why financial literacy is not optional for life sciences founders and CEOs. I have worked with brilliant Ph.D. scientists who understand their technology better than anyone else in the room, yet struggle to explain how that technology creates economic value. They … Read more
The Translation Failure: Why Good Science Is Not Enough I have watched promising life sciences companies fail for reasons that had surprisingly little to do with the quality of their science. The technology was compelling. The clinical rationale was defensible. The unmet medical need was real. Yet the company struggled to raise capital, secure a … Read more
Dual Fluency: How Life Sciences Leaders Master the Language of Science and Capital September 17, 2026by admin The cover tells the story of Dual Fluency visually. On one side is the language of science, represented by molecular structures and scientific networks in turquoise. On the other is the language of capital, represented by financial markets … Read more
Before navigating today’s volatile market, leaders seeking to bridge the divide between discovery and enterprise value should read Dr. David H. Crean’s Dual Fluency: Bridging Science, Capital, and Governance in Life Sciences. The book delivers an essential framework for executives, researchers, and board members to master both biological validation and complex corporate finance. By reading … Read more
This industry has a long tradition of softening the truth about what leadership failure actually costs. But if we look closely, we would realize that life sciences is a tournament, somewhat analogous to the NCAA’s March Madness. Out of every 10,000 potential drug compounds screened in preclinical research, only one will eventually receive FDA approval. … Read more
In biopharma, the most dangerous stretch of road is neither the initial hypothesis nor the final launch. It is the treacherous, capital-intensive space between early discovery and full-scale commercialization where hundreds of promising therapeutics go to die. While conventional wisdom points to clinical trial failures and unpredicted toxicity as the primary cause of death, you … Read more
Have you ever wondered why extraordinary scientific breakthroughs quietly vanish every year? A novel molecule demonstrates breathtaking target selectivity in vitro, cures disease models in mice, and generates glowing peer-reviewed papers in high-impact journals. Yet, three years later, the spinout behind it has quietly liquidated, the lab stands empty, and the intellectual property sits gathering … Read more